Baxter Updates Executive Severance Plan and Governance Framework

Baxter International ( (BAX) ) has shared an update.

On May 4, 2026, Baxter’s board approved a new Executive Severance and Change in Control Plan that replaces its prior severance program and standardizes benefits for vice presidents and above, including Interim CFO Anita Zielinski and other named executive officers but excluding CEO Andrew Hider, whose severance terms are governed by his existing offer letter. The plan broadens the definition of a qualifying termination to include resignations for good reason and reductions-in-force, adds tiered and enhanced payouts tied to change-in-control events, preserves non‑CIC severance levels for previously covered executives, and requires releases and restrictive covenants as a condition for benefits.

In connection with the new plan, independent directors amended Hider’s offer letter to extend the cash payment covering employer health-benefit costs in a non‑CIC termination from 18 months to 24 months, aligning his treatment more closely with the new framework while still maintaining separate contractual terms. At the May 5, 2026 annual meeting, shareholders elected nine directors, endorsed 2025 executive pay on an advisory basis, ratified PricewaterhouseCoopers as 2026 auditor, approved an amended incentive plan, and backed a charter change and related bylaw amendments that set the board size between seven and twelve directors, reinforcing Baxter’s governance structure and board flexibility.

The most recent analyst rating on (BAX) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.

Spark’s Take on BAX Stock

According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.

The score is primarily constrained by weak profitability and a still-levered balance sheet despite improving cash flow, alongside bearish price trends. The earnings call adds modest support via reiterated full-year targets and an expected second-half margin recovery, but meaningful operational and margin headwinds keep the overall profile below average.

To see Spark’s full report on BAX stock, click here.

More about Baxter International

Baxter International Inc. is a global healthcare company that develops and manufactures medical products and therapies, including hospital and renal care solutions, for patients and providers worldwide. The company operates in highly regulated healthcare markets, where executive leadership stability and strong corporate governance are closely watched by investors and other stakeholders.

Average Trading Volume: 9,491,659

Technical Sentiment Signal: Sell

Current Market Cap: $9.03B

For detailed information about BAX stock, go to TipRanks’ Stock Analysis page.